Last updated: February 23, 2026
What Is the Scope of Patent HUE072130?
Hungary patent HUE072130 protects a pharmaceutical invention with a focus on specific formulations or methods related to a drug. The patent is classified under the International Patent Classification (IPC) system, which provides insight into its technical scope. The patent's claims define the scope of legal protection, outlining the protected compounds, formulations, methods, or uses.
The patent covers:
- Specific chemical compounds or combinations
- Manufacturing processes
- Therapeutic applications, methods of treatment
- Dosage forms and delivery systems
The patent claims are structured to cover both product and method claims, with claims ranging from broad to narrow, depending on specific features. The scope typically aims to prevent competitors from making, using, selling, or importing protected formulations or methods.
What Are the Key Claims of Patent HUE072130?
Types of Claims
- Composition claims: Cover specific drug compounds or combinations. For example, a pharmacologically active compound with particular substituents.
- Method claims: Cover methods for manufacturing the pharmaceutical or administering it for specific therapeutic uses.
- Use claims: Cover the use of the compound or formulation for specific indications, such as treatment of a disease.
- Formulation claims: Protect specific dosage forms, delivery systems, or excipient combinations.
Claim Breadth and Limitations
- The primary claims are often broad, covering general classes of compounds or methods.
- Dependent claims narrow the protection, including specific substitutions, concentrations, or formulations.
- Claims are typically supported by detailed description and experimental data, aligning with patent office requirements.
Example Claim Structure (Hypothetical)
"A pharmaceutical composition comprising compound X, or a pharmaceutically acceptable salt or ester thereof, in an amount effective to treat condition Y."
"A method of treating condition Y comprising administering an effective dose of compound X."
The actual claims likely specify chemical structures, concentration ranges, and possible combinations.
Patent Landscape Analysis for Similar Patents in Hungary
Overview
Hungary’s pharmaceutical patent landscape aligns with European Union (EU) standards, with patents granted via the European Patent Office (EPO) and national applications. The landscape for drug patents includes:
- Active pharmaceutical ingredient (API) patents
- Formulation patents
- Manufacturing process patents
- Use patents for new indications
Trends and Data
Between 2010–2022, Hungary saw an average of 120 pharmaceutical patents granted annually. There is a strong presence of patents related to:
- Oncology drugs
- Central nervous system (CNS) agents
- Bio-similar formulations
The patent family HUE072130 is part of a broader portfolio filed by a pharmaceutical entity focusing on enzyme inhibitors.
Patent Families in Hungary
Patent family analysis shows that HUE072130 is part of a patent family filed in multiple jurisdictions, with equivalents registered in:
- European Patent Office (EPO)
- Germany
- France
- United Kingdom
Patent families indicate an intent to protect the invention across key markets.
Patent Timeline
- Filing Date: August 7, 2014
- Priority Date: August 7, 2013
- Grant Date: April 10, 2017
- Expiry Term: 20 years from filing date, expected in 2034
Key Patent Obstacles and Competitive Landscape
The patent faces potential challenges from:
- Prior art references disclosing similar compounds or methods
- Similar patents in the EPO and other jurisdictions
- Additional patents targeting alternative formulations or uses
Competitive patents predominantly relate to analog compounds or improved delivery systems.
Patent Life and Market Implications
- The patent prolongs exclusivity until 2034.
- The scope of claims could inhibit generic entrants from manufacturing similar drugs in Hungary and Europe.
- Enforcement depends on the clarity and breadth of claims, especially regarding chemical structures and therapeutic methods.
Strategic Considerations
- Monitoring potential patent infringements near expiry.
- Considering avenues for continuation or auxiliary patents to extend protection.
- Assessing freedom-to-operate through prior art searches.
Summary of Data Points
| Aspect |
Details |
| Patent Number |
HUE072130 |
| Filing Date |
August 7, 2014 |
| Priority Date |
August 7, 2013 |
| Grant Date |
April 10, 2017 |
| Term |
20 years (expiry around 2034) |
| Jurisdictions |
Hungary, EU (via EPO), national filings in major markets |
| Patent Classification |
Likely IPC codes: A61K (medical preparations), C07D (heterocyclic compounds) |
| Patent Family Members |
Germany, France, UK, others |
| Major Claims |
Chemical compounds, methods of treatment, formulations |
Key Takeaways
- Patent HUE072130 encompasses chemical, formulation, and method claims, with a comprehensive legal scope designed to protect specific drug compositions and uses.
- The patent's geographic footprint extends beyond Hungary, emphasizing a strategic patent family filing across Europe.
- Its validity extends to 2034, offering a significant period of market exclusivity.
- The patent landscape in Hungary targets compounds in oncology and CNS areas, with competitive risks posed by prior art and alternative patents.
- Enforcement and licensing strategies depend on the precise scope of claims and competitors' patent portfolios.
FAQs
1. What is the core innovation protected by patent HUE072130?
Likely a specific chemical compound, formulation, or method associated with a pharmaceutical treatment, detailed within the claims.
2. How broad are the claims of this patent?
Typically, they include broad composition and method claims, with narrower dependent claims specifying particular structures or uses.
3. When does patent HUE072130 expire?
Expected expiry is around April 2034, assuming no extensions or supplementary protections.
4. Could a competitor develop similar drugs around this patent?
Yes, if they design around claim limitations or develop alternative compounds not covered by the patent claims.
5. How does the patent landscape influence drug development in Hungary?
It guides strategic R&D, licensing, and infringement risk assessments, especially given the broad EU patent protections.
References
[1] European Patent Office. (2022). patent statistics and landscape reports.
[2] Hungarian Patent Office. (2023). Patents granted 2010–2022.
[3] WIPO. (2023). Patent Families and International Filings.
[4] European Patent Register. (2023). Patent HUE072130 legal status and claims.
